Correlation between glycosylated hemoglobin and testosterone in non-obese male patients with type 2 diabetes mellitus

doi:10.3877/cma.j.issn.2095-655X.2022.02.006

Abstract

Abstract:

Objective

To investigate the correlation between glycosylated hemoglobin (HbA_1c)and serum total testosterone (TT) level in non-obese male patients with type 2 diabetes mellitus (T2DM).

Methods

A total of 387 non-obese male T2DM patients hospitalized in the Endocrinology Department, Affiliated Hospital of Jining Medical University from November 2019 to April 2021 were selected. Their baseline clinical data were collected and grouped according to the quartile of HbA_1c level to compare the differences of TT levels among the four groups. The link between HbA_1c and TT level was investigated using Pearson correlation analysis and multiple linear regression.

Results

The TT level was 3.97 (3.06, 4.98)ng/mL in non-obese male T2DM patients, with testosterone insufficiency (<3.5 ng/mL) accounting for 36.43%(141/387). According to the quartile of HbA_1c level, TT levels decreased as HbA_1c levels increased, and the difference was statistically significant (F=2.99, P<0.05). Pearson correlation analysis showed that TT was negatively correlated with HbA_1c (r=-0.13), waist circumference (r=-0.14), WHT (r=-0.12), TG (r=-0.16), fasting C-peptide (r=-0.24), and positively correlated with HDL-C (r=0.19) (all P<0.05). Multiple linear regression analysis included TT and HbA_1c, age, waist circumference, WHT, HDL-C, TG, and fasting C-peptide. In non-obese male T2DM patients, HbA_1c was found to be significantly adversely linked with TT (B=-0.18, P<0.01).

Conclusion

In non-obese male T2DM patients, HbA_1c is inversely linked with TT level.

Key words: Diabetes mellitus, type 2, Glycosylated hemoglobin, Testosterone, Men, Non-obesity

Yaru Wang, Fang Liu, Zonglan Chen, Mei Zhang, Bo Ban. Correlation between glycosylated hemoglobin and testosterone in non-obese male patients with type 2 diabetes mellitus[J]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(02): 99-103.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2022.02.006

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2022/V10/I02/99

Figures/Tables 4

References 21

[1]	Lunenfeld B, Mskhalaya G, Zitzmann M，et al.Recommendations on the diagnosis，treatment and monitoring of testosterone deficiency in men[J]．Aging Male，2021，24(1):119-138.DOI：10.1080/13685538.2021.1962840.
[2]	Basat S, Sivritepe R, Ortaboz D，et al.The relationship between vitamin D level and erectile dysfunction in patients with type 2 diabetes mellitus[J]．Aging Male，2018，21(2):111-115.DOI：10.1080/13685538.2017.1379488.
[3]	Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I，et al.Prevalence and independent risk factors for erectile dysfunction in Spain：results of the Epidemiologia de la Disfuncion Erectil Masculina Study[J]．J Urol，2001，166(2):569-574; discussion 574-575.DOI：10.1016/s0022-5347(05)65986-1.
[4]	Tamrakar D, Bhatt DS, Sharma VK，et al.Association between erectile dysfunction and type 2 diabetes mellitus[J]．J Nepal Health Res Counc，2021，19(2):378-383.DOI：10.33314/jnhrc.v19i2.3394.
[5]	Peyton CC, Colaco MA, Kovell RC，et al.Erectile Dysfunction is Predictive of Endothelial Dysfunction in a Well Visit Population[J]．J Urol，2016，195(4 Pt 1):1045-1050.DOI：10.1016/j.juro.2015.11.037.
[6]	Maiorino MI, Bellastella G, Esposito K. Diabetes and sexual dysfunction：current perspectives[J]．Diabetes Metab Syndr Obes，2014，7:95-105.DOI：10.2147/DMSO.S36455.
[7]	Chan J, Sauvé B, Tokmakejian S, Koren G，et al.Measurement of cortisol and testosterone in hair of obese and non-obese human subjects.Exp Clin Endocrinol Diabetes.2014;122(6):356-362.DOI：10.1055/s-0034-1374609.
[8]	中国2型糖尿病防治指南(2017年版)[J]．中国实用内科杂志，2018，38(04):292-344.
[9]	Corona G, Goulis DG, Huhtaniemi I，et al.European Academy of Andrology (EAA) guidelines on investigation，treatment and monitoring of functional hypogonadism in males：Endorsing organization：European Society of Endocrinology.Andrology.2020;8(5):970-987.DOI：10.1111/andr.12770.
[10]	Kim JS, Kim BS, Jeon JY，et al.Testosterone deficiency associated with poor glycemic control in korean male diabetics[J]．Endocrinol Metab (Seoul)，2014，29(3):300-306.DOI：10.3803/EnM.2014.29.3.300.
[11]	廖小平，沈洁．男性2型糖尿病患者血糖与雄激素水平的相关性[J]．中外医疗，2019，38(4):32-34.DOI：10.16662/j.cnki.1674-0742.2019.04.032.
[12]	Farooq R, Bhat MH, Majid S，et al.Association between T2DM and the lowering of testosterone levels among Kashmiri males[J]．Arch Endocrinol Metab，2021，64(5):528-532.DOI：10.20945/2359-3997000000288.
[13]	Keating NL, Liu PH, O&#x27，et al.Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer[J]．Eur Urol，2014，65(4):816-824.DOI：10.1016/j.eururo.2013.02.023.
[14]	Yassin DJ, Doros G, Hammerer PG，et al.Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life[J]．J Sex Med，2014，11(6):1567-1576.DOI：10.1111/jsm.12523.
[15]	Yassin A, Haider A, Haider KS，et al.Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes：Eight-Year Data From a Registry Study[J]．Diabetes Care，2019，42(6):1104-1111.DOI：10.2337/dc18-2388.
[16]	Haider KS, Haider A, Saad F，et al.Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes：11-year data from a real-world registry study[J]．Diabetes Obes Metab，2020，22(11):2055-2068.DOI：10.1111/dom.14122.
[17]	Rao PM, Kelly DM, Jones TH.Testosterone and insulin resistance in the metabolic syndrome and T2DM in men[J]．Nat Rev Endocrinol，2013，9(8):479-493.DOI：10.1038/nrendo.2013.122.
[18]	Zhu L, Zhou J, Pan Y，et al.Glucagon-like peptide-1 receptor expression and its functions are regulated by androgen[J]．Biomed Pharmacother，2019，120:109555.DOI：10.1016/j.biopha.2019.109555.
[19]	Mauvais-Jarvis F. Androgen-deprivation therapy and pancreatic β-cell dysfunction in men[J]．J Diabetes Complications，2016，30(3):389-390.DOI：10.1016/j.jdiacomp.2016.01.007.
[20]	Navarro G, Xu W, Jacobson DA，et al.Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the Male[J]．Cell Metab，2016，23(5):837-851.DOI：10.1016/j.cmet.2016.03.015.
[21]	Corrales JJ, Burgo RM, Garca-Berrocal B，et al.Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control[J]．Metabolism，2004，53(5):666-672.DOI：10.1016/j.metabol.2003.12.016.

项目	水平
年龄(岁，±s)	53.97±11.84
DM病程[年，M(P₂₅，P₇₅)]	8.00(3.00，12.00)
SBP(mmHg，±s)	133.23±16.25
DBP(mmHg，±s)	80.27±11.16
BMI (kg/m²，±s)	24.78±2.14
腰围(cm，±s)	92.43±6.76
WHT(±s)	0.93±0.51
E₂(pmol/L，±s)	40.13±12.13
TT[ng/mL，M(P₂₅，P₇₅)]	3.97(3.06，4.98)
FSH[U/L，M(P₂₅，P₇₅)]	7.33(4.89，10.76)
LH[U/L，M(P₂₅，P₇₅)]	5.12(3.53，7.34)
ALT[U/L，M(P₂₅，P₇₅)]	18.15(13.20，25.58)
AST[U/L，M(P₂₅，P₇₅)]	15.00(13.00，20.00)
Cr[μmol/L，M(P₂₅，P₇₅)]	64.20(55.80，73.30)
UA(μmol/L，±s)	310.17 ± 82.10
TG [mmol/L，M(P₂₅，P₇₅)]	1.35(0.96，2.02)
TC (mmol/L，±s)	4.40±1.22
HDL-C (mmol/L，±s)	1.14±0.27
LDL-C (mmol/L，±s)	2.72±0.87
FBG (mmol/L，±s)	7.17±1.86
HbA_1c (%，±s)	8.99±1.98
空腹C肽(ng/mL，±s)	2.20±1.08

项目	水平
年龄(岁，±s)	53.97±11.84
DM病程[年，M(P₂₅，P₇₅)]	8.00(3.00，12.00)
SBP(mmHg，±s)	133.23±16.25
DBP(mmHg，±s)	80.27±11.16
BMI (kg/m²，±s)	24.78±2.14
腰围(cm，±s)	92.43±6.76
WHT(±s)	0.93±0.51
E₂(pmol/L，±s)	40.13±12.13
TT[ng/mL，M(P₂₅，P₇₅)]	3.97(3.06，4.98)
FSH[U/L，M(P₂₅，P₇₅)]	7.33(4.89，10.76)
LH[U/L，M(P₂₅，P₇₅)]	5.12(3.53，7.34)
ALT[U/L，M(P₂₅，P₇₅)]	18.15(13.20，25.58)
AST[U/L，M(P₂₅，P₇₅)]	15.00(13.00，20.00)
Cr[μmol/L，M(P₂₅，P₇₅)]	64.20(55.80，73.30)
UA(μmol/L，±s)	310.17 ± 82.10
TG [mmol/L，M(P₂₅，P₇₅)]	1.35(0.96，2.02)
TC (mmol/L，±s)	4.40±1.22
HDL-C (mmol/L，±s)	1.14±0.27
LDL-C (mmol/L，±s)	2.72±0.87
FBG (mmol/L，±s)	7.17±1.86
HbA_1c (%，±s)	8.99±1.98
空腹C肽(ng/mL，±s)	2.20±1.08

项目	Q1(HbA_1c<7.50%)(n＝94)	Q2(7.50%≤HbA_1c<8.70%)(n＝97)	Q3(8.70%≤HbA_1c<10.40%)(n＝97)	Q4(HbA_1c≥10.40%)(n＝99)	F值	P值
TT(ng/mL，±s)	4.37±1.57	4.31±1.65	4.01±1.33	3.82±1.37	2.99	0.03
E₂(pmol/L，±s)	40.79±12.33	40.32±11.90	39.35±11.46	40.05±12.92	0.23	0.88
FSH[U/L，M(P₂₅，P₇₅)]	7.44(4.84，10.65)	7.13(4.70，12.69)	7.90(5.12，11.48)	7.06(4.82，9.97)	0.65	0.58
LH[U/L，M(P₂₅，P₇₅)]	5.24(3.42，7.82)	4.88(3.52，7.42)	5.47(3.97，7.33)	4.97(3.13，6.95)	0.98	0.40

项目	Q1(HbA_1c<7.50%)(n＝94)	Q2(7.50%≤HbA_1c<8.70%)(n＝97)	Q3(8.70%≤HbA_1c<10.40%)(n＝97)	Q4(HbA_1c≥10.40%)(n＝99)	F值	P值
TT(ng/mL，±s)	4.37±1.57	4.31±1.65	4.01±1.33	3.82±1.37	2.99	0.03
E₂(pmol/L，±s)	40.79±12.33	40.32±11.90	39.35±11.46	40.05±12.92	0.23	0.88
FSH[U/L，M(P₂₅，P₇₅)]	7.44(4.84，10.65)	7.13(4.70，12.69)	7.90(5.12，11.48)	7.06(4.82，9.97)	0.65	0.58
LH[U/L，M(P₂₅，P₇₅)]	5.24(3.42，7.82)	4.88(3.52，7.42)	5.47(3.97，7.33)	4.97(3.13，6.95)	0.98	0.40

变量	r值	P值
HbA_1c(%)	－0.13	0.01
年龄(岁)	0.06	0.28
DM病程(年)	0.09	0.08
BMI(kg/m²)	－0.09	0.07
腰围(cm)	－0.14	0.01
WHT	－0.12	0.02
SBP(mmHg)	－0.06	0.25
DBP(mmHg)	－0.09	0.08
TG(mmol/L)	－0.16	0.002
TC(mmol/L)	0.06	0.26
HDL-C(mmol/L)	0.19	<0.01
LDL-C(mmol/L)	0.10	0.05
ALT(U/L)	－0.07	0.19
AST(U/L)	－0.04	0.41
Cr(μmol/L)	0.03	0.55
UA(μmol/L)	－0.006	0.90
FBG(mmol/L)	－0.03	0.61
空腹C肽(ng/mL)	－0.24	<0.01

Please choose a citation manager

Content to export